Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
NCT05389527
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
43
Enrollment
OTHER
Sponsor class
Conditions
Carcinoma, Hepatocellular
Interventions
DRUG:
Pembrolizumab+Lenvatinib
Sponsor
Shanghai Zhongshan Hospital
Collaborators
[object Object]